Quidel to Host 2018 Analyst and Investor Day in Chicago
March 27 2018 - 5:00PM
Business Wire
Quidel Corporation (NASDAQ: QDEL), a provider of rapid
diagnostic testing solutions, cellular-based virology assays and
molecular diagnostic systems, will host its 2018 Quidel Analyst and
Investor Day at the Hyatt Regency O’Hare hotel in Chicago, Illinois
on Tuesday, April 3, 2018.
Quidel’s management presentation will begin at 12:30 p.m.
Central Time with a question and answer session scheduled
immediately following the management presentation. During the
presentation, the Company will discuss business and financial
developments and trends. The Company's statements may contain or
constitute material information that has not been previously
disclosed. For further details about the event, please contact
Ruben Argueta at rargueta@quidel.com.
A live webcast and audio archive of the presentation will be
available via the Investor Relations section of the company’s Web
site at http://ir.quidel.com. Participants should allow
approximately five to ten minutes prior to the presentation's start
time to visit the site and download any streaming media software
needed to listen to the Internet webcast. A replay of the webcast
will also be available on the company’s Web site for 14 days.
About Quidel Corporation
Quidel Corporation serves to enhance the health and
well-being of people around the globe through the development of
diagnostic solutions that can lead to improved patient outcomes and
provide economic benefits to the healthcare system. Marketed under
the Sofia®, QuickVue®, D3® Direct Detection, Thyretain®, Triage®
and InflammaDry® leading brand names, as well as under the new
Solana®, AmpliVue® and Lyra® molecular diagnostic brands, Quidel’s
products aid in the detection and diagnosis of many critical
diseases and conditions, including, among others, influenza,
respiratory syncytial virus, Strep A, herpes, pregnancy, thyroid
disease and fecal occult blood. Quidel's recently
acquired Triage® system of tests comprises a comprehensive test
menu that provides rapid, cost-effective treatment decisions at the
point-of-care (POC), offering a diverse immunoassay menu in a
variety of tests to provide healthcare providers with diagnostic
answers for quantitative BNP, CK-MB, d-dimer, myoglobin, troponin I
and qualitative TOX Drug Screen. Quidel’s research and development
engine is also developing a continuum of diagnostic solutions from
advanced immunoassay to molecular diagnostic tests to further
improve the quality of healthcare in physicians’ offices and
hospital and reference laboratories. For more information about
Quidel’s comprehensive product portfolio,
visit quidel.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180327006336/en/
Quidel Contact:Quidel CorporationRandy StewardChief Financial
Officer(858) 552-7931orMedia and Investors Contact:Quidel
CorporationRuben Argueta(858) 646-8023rargueta@quidel.com
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
QuidelOrtho (NASDAQ:QDEL)
Historical Stock Chart
From Apr 2023 to Apr 2024